BioXcel Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BioXcel Therapeutics, Inc. (BTAI) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $358.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- BioXcel Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $358.00K, a 76.99% decline year-over-year.
- BioXcel Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $532.00K, a 195.56% increase year-over-year.
- BioXcel Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $581.00K, a 68.85% decline year-over-year.
- BioXcel Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.56M, a 47.21% increase year-over-year.
- BioXcel Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.67M, a 56.64% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.16M, a 66.93% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $18.61M, a 7.37% increase from fiscal 2022.
- BioXcel Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $17.34M, a 10.89% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $358.00K 10-Q · filed 2026-08-13 | $890.00K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $532.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $2.67M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $581.00K 10-Q · filed 2025-11-12 | $2.14M derived: sum of 2 quarters · filed 2026-08-13 | $2.32M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $1.56M 10-Q · filed 2026-08-13 | $1.74M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $180.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $6.16M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $1.86M 10-Q · filed 2025-11-12 | $2.92M derived: sum of 2 quarters · filed 2025-11-12 | $6.36M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.06M 10-Q · filed 2025-11-12 | $4.49M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $3.43M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $18.61M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $4.01M 10-Q · filed 2024-11-14 | $10.14M derived: sum of 2 quarters · filed 2024-11-14 | $15.02M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $6.12M 10-Q · filed 2024-11-14 | $11.00M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $4.88M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $17.34M 10-K · filed 2024-03-22 | |||
| 2022-09-30 | $4.48M 10-Q · filed 2023-11-14 | $8.96M derived: sum of 2 quarters · filed 2023-11-14 | $12.79M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $4.48M 10-Q · filed 2023-11-14 | $8.31M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $3.83M 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $19.45M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $4.88M 10-Q · filed 2022-11-14 | $11.65M derived: sum of 2 quarters · filed 2022-11-14 | $17.22M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $6.77M 10-Q · filed 2022-11-14 | $12.33M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $5.57M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $14.61M 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $5.27M 10-Q · filed 2021-11-10 | $7.22M derived: sum of 2 quarters · filed 2021-11-10 | $8.00M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $1.96M 10-Q · filed 2021-11-10 | $2.73M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $776.00K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $3.14M 10-K · filed 2021-03-12 | |||
| 2019-09-30 | $776.00K 10-Q · filed 2020-11-12 | $1.81M derived: sum of 2 quarters · filed 2020-11-12 | $2.49M derived: sum of 3 quarters · filed 2020-11-12 | |
| 2019-06-30 | $1.03M 10-Q · filed 2020-11-12 | $1.71M derived: sum of 2 quarters · filed 2020-11-12 | ||
| 2019-03-31 | $682.00K 10-Q · filed 2020-11-12 | |||
| 2018-12-31 | $3.08M 10-K · filed 2020-03-09 | |||
| 2018-09-30 | $889.00K 10-Q · filed 2019-11-14 | $1.63M derived: sum of 2 quarters · filed 2019-11-14 | $2.95M derived: sum of 3 quarters · filed 2019-11-14 | |
| 2018-06-30 | $740.00K 10-Q · filed 2019-11-14 | $2.06M derived: sum of 2 quarters · filed 2019-11-14 | ||
| 2018-03-31 | $1.32M 10-Q · filed 2019-11-14 | |||
| 2017-12-31 | $1.41M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |